Repligen to Acquire BioLife for $1.5 Billion, Positioning Itself at the Cell Therapy Manufacturing “Preservation Gate”

The manufacturing challenges of cell therapy are not limited to whether enough cells can be cultured, but also include whether these living cells can withstand freezing, transportation, and thawing after leaving the manufacturing site while maintaining quality. Bioprocessing equipment provider Repligen has agreed to acquire BioLife Solutions for an enterprise value of approximately $1.5 billion, aiming to bring this often-overlooked preservation gate—which directly affects whether therapies can be used—into its product portfolio.

Under the transaction agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen stock for each share they hold; fractional shares will be paid in cash. Approximately 64% of the transaction value will consist of Repligen stock and 36% will be cash, with Repligen expected to use approximately $564 million and issue 7.2 million shares of its stock. The boards of directors of both companies have unanimously approved the agreement.

BioLife’s core value lies in the integration of its biopreservation media and cell-processing tools into cell and gene therapy manufacturing processes. These products are used to reduce cell damage caused by freezing and thawing and to support material management from research and development and clinical trials through commercial supply. BioLife products currently support 18 approved therapies, enabling Repligen to enter directly into a cell therapy supply chain with existing commercial demand, rather than merely betting on an emerging market that has yet to mature.

Repligen’s existing business focuses on filtration, chromatography, process analytics, fluid management, and other areas required for biologic drug manufacturing. After adding BioLife, its product range could extend further into the preservation and processing of living cellular materials. For therapies using autologous cells, patient cells travel among collection centers, manufacturing facilities, and treating hospitals. Any preservation failure could result in the loss of a batch or even delay treatment. Preservation media therefore receive less attention than therapeutic molecules, but are an important foundation of manufacturing reliability.

Background

As cell therapy moves from small numbers of clinical batches toward larger-scale supply, industry competition is gradually shifting toward automation, closed-system operations, transportation across multiple sites, and consistent quality control. BioLife fills the part of this manufacturing infrastructure that is directly related to cell condition. For Repligen, the transaction could also increase its engagement with therapy developers at different process stages, creating a more comprehensive portfolio of consumables and tools.

The transaction is not yet final. Completion of the acquisition requires approval from BioLife shareholders, antitrust clearance, the effectiveness of Repligen’s Form S-4 registration statement, and Nasdaq approval for the listing of the newly issued shares. Under certain circumstances, BioLife may be required to pay a $59 million termination fee. The companies expect to complete the transaction in the fourth quarter of 2026, and Repligen estimates that it will retain more than $300 million in pro forma cash and cash equivalents after closing.

The information disclosed about the transaction primarily explains the product complementarity and financial structure, and is not yet sufficient to determine customer retention, revenue growth, or cost efficiencies following integration. BioLife products support multiple approved therapies, indicating that they already have an established commercial foundation. However, whether Repligen can turn preservation media, cell processing, and its existing bioprocessing tools into stable cross-selling opportunities will still depend on regulatory review, the closing of the transaction, and the execution of the subsequent integration.